Cerebrospinal fluid cytotoxicity does not affect survival in amyotrophic lateral sclerosis. 2017

L Galán, and J Matías-Guiu, and J A Matias-Guiu, and M Yáñez, and V Pytel, and A Guerrero-Sola, and A Vela-Souto, and J A Arranz-Tagarro, and U Gómez-Pinedo, and A G García
Department of Neurology, Institute of Neurosciences, Hospital Clínico San Carlos, San Carlos Institute for Health Research (IdISSC), Universidad Complutense de Madrid, Madrid, Spain.

OBJECTIVE Cerebrospinal fluid (CSF) from some patients with amyotrophic lateral sclerosis (ALS) has been demonstrated to significantly reduce the neuronal viability of primary cell cultures of motor neurons. We aimed to study the potential clinical consequences associated with the cytotoxicity of CSF in a cohort of patients with ALS. METHODS We collected CSF from thirty-one patients with ALS. We analysed cytotoxicity by incubating it into the primary cultures of motor cortex neurons. Neural viability was quantified after 24 hours using the colorimetric MTT reduction assay. All patients were followed up from the moment of diagnosis to death, and a complete evaluation during disease progression and survival was performed, including gastrostomy and respiratory assistance. RESULTS Twenty-one patients (67.7%) presented a cytotoxic CSF. There were no significant differences between patients with and without cytotoxicity regarding mean time from symptom onset to the diagnosis, from the diagnosis to death, from the diagnosis to respiratory assistance with BIPAP, from diagnosis to gastrostomy and from the onset of symptoms to death. In Cox regression analysis, bulbar onset, but not cytotoxicity, gender or age at onset, was associated with a lower risk of survival. CONCLUSIONS Cerebrospinal fluid cytotoxicity was not associated with differential survival rates. This suggests that the presence of cytotoxicity in CSF, measured through neuronal viability in primary cultures of motor cortex neurons, could reflect different mechanisms of the disease, but it does not predict disease outcome.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009046 Motor Neurons Neurons which activate MUSCLE CELLS. Neurons, Motor,Alpha Motorneurons,Motoneurons,Motor Neurons, Alpha,Neurons, Alpha Motor,Alpha Motor Neuron,Alpha Motor Neurons,Alpha Motorneuron,Motoneuron,Motor Neuron,Motor Neuron, Alpha,Motorneuron, Alpha,Motorneurons, Alpha,Neuron, Alpha Motor,Neuron, Motor
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002555 Cerebrospinal Fluid A watery fluid that is continuously produced in the CHOROID PLEXUS and circulates around the surface of the BRAIN; SPINAL CORD; and in the CEREBRAL VENTRICLES. Cerebro Spinal Fluid,Cerebro Spinal Fluids,Cerebrospinal Fluids,Fluid, Cerebro Spinal,Fluid, Cerebrospinal,Fluids, Cerebro Spinal,Fluids, Cerebrospinal,Spinal Fluid, Cerebro,Spinal Fluids, Cerebro
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000690 Amyotrophic Lateral Sclerosis A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94) ALS - Amyotrophic Lateral Sclerosis,Lou Gehrig Disease,Motor Neuron Disease, Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis With Dementia,Amyotrophic Lateral Sclerosis, Guam Form,Amyotrophic Lateral Sclerosis, Parkinsonism-Dementia Complex of Guam,Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 1,Charcot Disease,Dementia With Amyotrophic Lateral Sclerosis,Gehrig's Disease,Guam Disease,Guam Form of Amyotrophic Lateral Sclerosis,Lou Gehrig's Disease,Lou-Gehrigs Disease,ALS Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis Parkinsonism Dementia Complex 1,Amyotrophic Lateral Sclerosis, Parkinsonism Dementia Complex of Guam,Disease, Guam,Disease, Lou-Gehrigs,Gehrig Disease,Gehrigs Disease,Sclerosis, Amyotrophic Lateral

Related Publications

L Galán, and J Matías-Guiu, and J A Matias-Guiu, and M Yáñez, and V Pytel, and A Guerrero-Sola, and A Vela-Souto, and J A Arranz-Tagarro, and U Gómez-Pinedo, and A G García
July 2017, Acta neurologica Scandinavica,
L Galán, and J Matías-Guiu, and J A Matias-Guiu, and M Yáñez, and V Pytel, and A Guerrero-Sola, and A Vela-Souto, and J A Arranz-Tagarro, and U Gómez-Pinedo, and A G García
September 1999, European journal of neurology,
L Galán, and J Matías-Guiu, and J A Matias-Guiu, and M Yáñez, and V Pytel, and A Guerrero-Sola, and A Vela-Souto, and J A Arranz-Tagarro, and U Gómez-Pinedo, and A G García
February 2018, Annals of neurology,
L Galán, and J Matías-Guiu, and J A Matias-Guiu, and M Yáñez, and V Pytel, and A Guerrero-Sola, and A Vela-Souto, and J A Arranz-Tagarro, and U Gómez-Pinedo, and A G García
April 1992, Annals of neurology,
L Galán, and J Matías-Guiu, and J A Matias-Guiu, and M Yáñez, and V Pytel, and A Guerrero-Sola, and A Vela-Souto, and J A Arranz-Tagarro, and U Gómez-Pinedo, and A G García
April 2007, Neuroscience letters,
L Galán, and J Matías-Guiu, and J A Matias-Guiu, and M Yáñez, and V Pytel, and A Guerrero-Sola, and A Vela-Souto, and J A Arranz-Tagarro, and U Gómez-Pinedo, and A G García
January 1984, Journal of neurology,
L Galán, and J Matías-Guiu, and J A Matias-Guiu, and M Yáñez, and V Pytel, and A Guerrero-Sola, and A Vela-Souto, and J A Arranz-Tagarro, and U Gómez-Pinedo, and A G García
February 1979, Archives of neurology,
L Galán, and J Matías-Guiu, and J A Matias-Guiu, and M Yáñez, and V Pytel, and A Guerrero-Sola, and A Vela-Souto, and J A Arranz-Tagarro, and U Gómez-Pinedo, and A G García
January 2020, Brain communications,
L Galán, and J Matías-Guiu, and J A Matias-Guiu, and M Yáñez, and V Pytel, and A Guerrero-Sola, and A Vela-Souto, and J A Arranz-Tagarro, and U Gómez-Pinedo, and A G García
June 2000, Neuroreport,
L Galán, and J Matías-Guiu, and J A Matias-Guiu, and M Yáñez, and V Pytel, and A Guerrero-Sola, and A Vela-Souto, and J A Arranz-Tagarro, and U Gómez-Pinedo, and A G García
October 1993, Lancet (London, England),
Copied contents to your clipboard!